ACSL1 and Miyoshi myopathy: Overall, these data further support the idea that the ACSLs, especially ACSL4 and ACSL1, have associations with clinical outcome in newly‐diagnosed MM patients treated with proteasome inhibitor and/or IMiDs, and may be tested as novel targets.